Introduction to Scilex Holding Company
Pioneering company Scilex Holding Company (Nasdaq: SCLX) is concentrated on the development and marketing of non-opioid pain management solutions. Dedicated to enhancing patient quality of life, Scilex seeks to lead the worldwide pain management solution market. To guarantee responsible pharmaceutical development, the company operates under tight social, environmental, financial, and ethical standards.
Overview of the Master Distributor Agreement
By means of a Master Distributor Agreement with Devart Middle East Food Supplements and CH Trading Group LLC, Scilex has made a noteworthy step in increasing its worldwide presence. The leading non-opioid pain reliever ZTlido® is meant to be distributed into important markets, including Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa, under this agreement.
Strategic Objectives of the Agreement
Built on Scilex's current Product Distribution Agreement with CH Trading Group, the Master Distributor Agreement with CH Trading Group will keep broadening the commercialization of ZTlido® over the Middle East and North/South Africa markets. The agreement also offers a chance to spread Scilex's products over the larger Islamic world, possibly extending the cooperation to include other non-opioid painkillers from Scilex's portfolio.
Roles and Responsibilities
Devart Middle East will be the master distributor under the terms of the agreement, assuming major roles including marketing, sales, promotion, and ZTlido® distribution. A network of business associates functioning in the assigned areas will help facilitate the distribution. The market presence and availability of ZTlido® in these areas should be greatly improved by this cooperation.
In-Depth Look at ZTlido® and Its Market Impact
Approved by the U.S. Food and Drug Administration (FDA) for the relief of pain related to post-herpetic neuralgia (PHN), ZTlido® (lidocaine topical system) 1.8% is Scilex's flagship product. One kind of nerve pain that can follow shingles is PHN. With greatly enhanced adhesion and continuous pain relief over its 12-hour dosage period, ZTlido® has been deliberately developed to overcome the restrictions of current prescription lidocaine patches.
Key Benefits of ZTlido®
-Superior Adhesion: The strong adhesive capacity provided by ZTlido® guarantees that the patch stays in place during the treatment period, even during exercise or showering. -Continuous Pain Relief: For up to 12 hours, the product offers consistent pain relief, making it a dependable choice for people with persistent pain.
ZTlido®'s Success in the U.S. Market
Since its introduction, ZTlido® has shown amazing success on the American market.
-Over One Million Patients Treated: Symphony Health prescription data indicates that ZTlido® has been used for pain management by over a million American patients. -Number One Non-Opioid Pain Medication: Based on 2023 prescription data, ZTlido® is currently the most often prescribed non-opioid-branded pain reliever among pain experts in the United States. -High Patient Satisfaction: 89% of Scilex's 2023 patient survey respondents say their ZTlido® treatment either "completely" or "mostly" satisfied them.
Expanding the Non-Opioid Pain Management Portfolio
Not only is Scilex Holding Company concentrated on ZTlido®, but it is also aggressively broadening its non-opioid pain management portfolio. The company guarantees that patients have access to the best available treatments by being committed to providing creative ideas that solve different pain disorders.
Elyxyb®: A New Addition for Migraine Treatment
A recent addition to Scilex's product range is Elyxyb® (celecoxib oral solution). It is especially meant for adult acute migraine treatment, with or without an aura. Scilex intends to keep Elyxyb® commercialized in 2024, extending its products in the treatment of chronic pain.
GLOPERBA®: First Liquid Oral Colchicine for Gout Flare Prophylaxis
The first and only liquid oral form of colchicine, an anti-gout medicine, is GLOPERBA® (colchicine USP oral solution). The FDA approves it for adults' prophylactic treatment of painful gout flares. With a June 10, 2024, launch date, Scilex in-licensed the sole rights to commercialize GLOPERBA® in the United States. Scilex's pain management range is likely to feature this product as a mainstay.
Innovative Pipeline of Product Candidates
Scilex is actively building a pipeline of creative product candidates meant to offer non-opioid answers for different pain disorders. These contenders provide fresh treatment choices for patients and are meant to solve major unmet medical needs.
SP-102: A Novel Solution for Sciatica
Featuring 10 mg of dexamethasone, SP-102 is an injectable dexamethasone sodium phosphate viscous gel product. This new formulation is meant for epidural injections to treat sciatica, sometimes known as lumbosacral radicular pain. The FDA has a Fast Track designation for SP-102; should it be approved, it may be the first non-opioid epidural injection approved for sciatica. Providing a safer, non-additive alternative for pain management, this product could replace the 12 million off-label epidural steroid injections given annually in the United States.
SP-103: Next-Generation Lidocaine Topical System
Designed for the treatment of persistent neck pain, SP-103 is a next-generation, triple-strength formulation of ZTlido®. Scilex just finished an investigator-initiated Phase 2 study in chronic neck pain and a Phase 2 trial in acute low back pain with SP-103. The neck pain study's findings were written up in the Anesthesia journal. Given its use in treating low back pain, SP-103 has also been given Fast Track status by the FDA, presenting a potential new choice for sufferers.
SP-104: Low-Dose Naltrexone for Chronic Pain and Fibromyalgia
Designed for treatment of fibromyalgia and chronic pain, SP-104 is a 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) capsule. Offering the possibility of efficient pain relief without the hazards connected with opioid treatments, this product candidate offers a fresh approach to treating these difficult diseases.
Scilex’s Commitment to Ethical Pharmaceutical Development
Emphasizing social, environmental, and financial obligations, Scilex Holding Company runs with a great dedication to moral values. The company's goal is to create and market pharmacological products that improve patients' quality of life all around. Advancing this goal is greatly aided by Scilex Pharmaceuticals and Semnur Pharmaceuticals, both wholly-owned subsidiaries of Scilex Holding Company.
For further details on their products, see Scilex Holding Company https://www.scilexholding.com/.
